Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan


22 Nov 2020


e-Poster Display Session


Cytotoxic Therapy;  Clinical Research

Tumour Site


Masanobu Enomoto


Annals of Oncology (2020) 31 (suppl_6): S1273-S1286. 10.1016/annonc/annonc355


M. Enomoto1, T. Yamada2, M. Nakamura3, S. Ishiyama4, H. Yokomizo5, C. Kosugi6, H. Sonoda7, K. Ishibashi8, H. Kuramochi9, K. Nozawa10, Y. Yoshida11, R. Ohta12, S. Hasegawa11, D. Ichikawa13, Y. Hashiguchi10, K. Hirata14, K. Katsumata1, H. Ishida8, K. Koda6, K. Sakamoto4

Author affiliations

  • 1 Gastrointestinal And Pediatric Surgery, Tokyo Medical University, 1600023 - Shinjuku-ku/JP
  • 2 Department Of Gastroenterological Surgery, Nippon Medical University, 1138603 - Tokyo/JP
  • 3 Department Of Chemotherapy, Aizawa Hospital, 390-8510 - Matsumoto/JP
  • 4 Department Of Coloproctological Surgery, Juntendo University School of Medicine, Tokyo/JP
  • 5 Department Of Surgrry, Tokyo Women's Medical University Medical Center East, Tokyo/JP
  • 6 Department Of Surgery, Teikyo University Chiba Medical Center, Chiba/JP
  • 7 Department Of Gastroenterological Surgery, Nippon Medical University, Tokyo/JP
  • 8 Department Of Digestive Tract And General Surgery, Saitama Medical University, Saitama/JP
  • 9 Department Of Chemotherapy, Tokyo Women's Medical University Yachiyo Medical Center, Chiba/JP
  • 10 Department Of Surgery, Teikyo University School of Medicine, Tokyo/JP
  • 11 Department Of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka/JP
  • 12 Gastroenterological Surgery, Nippon Medical School Main Hospital, 113-8603 - Tokyo/JP
  • 13 First Department Of Surgery, Yamanashi University, Yamanashi/JP
  • 14 Department Of Surgery 1, University of Occupational & Environmental Health, Fukuoka/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 89P


RAS status can impact on efficacy of chemotherapy for patients with metastatic tumor. However, we reported that RAS mutated clone can emerge in patients with RAS wild tumor, which suggest that the genotype of the tissue obtained at the time of diagnosis might not accurately represent, who are treated with EGFR blockade. In this study, we evaluated whether RAS mutation in tissue and/or in circulating tumor DNA (ctDNA) impact on efficacy of regorafenib. This is the biomarker analysis of RECC study, a phase II multicenter clinical trial in Japan, that confirmed the safety and effectiveness of dose escalation therapy of regorafenib in metastatic colorectal cancer (mCRC).


We conducted dose-escalation study as a single-arm, prospective, non-randomized, multi-centered open label phase II trial in Japan (RECC study). We set a starting dose of 80 mg/day during the first seven days, then will be increased up to 120 or 160 mg/day weekly. Before first administration of regorafenib, we extracted ctDNA and examined RAS mutation in ctDNA using droplet digital PCR (ddPCR).


Fifty-eight patients with mCRC were registered in this study, and blood samples were available in 45 patients. In all obtained samples, ctDNA were successfully extracted from plasma and the quality and quantity of ctDNA were sufficient for genetic analysis. RAS mutation was detected in tumor tissue of 29 patients (64%) and in ctDNA of 21 patients (47%). In ctDNA, RAS mutation was detected in 21 of the 29 patients (72%) with RAS mutated tumor, and 6 of 16 patients with RAS wild tumor. Five of the 6 patients with RAS wild tumor were treated with EGFR blockade in previous treatment. RAS status both in tumor tissue and ctDNA had no impact on progression free survival and overall survival.


It was reported that RAS mutation has negative impact on efficacy of FTD/TPI. However, RAS mutation showed no impact on the efficacy of regorafenib. EGFR blockade have a potential to emerge RAS mutated clone. Thus, RAS status should be reconfirmed at the last minute before starting late line chemotherapy using liquid biopsy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.